Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD
Authors:
- 20 July 2010
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (9) , 2087-2095
Abstract
This study measured the effects of atomoxetine HCl on high-risk behaviors and health-related quality of life in adolescents with attention-deficit/hyperactivity disorder (ADHD), using a subgroup analysis of data from a previous clinical trial. In the base study, which was conducted at 26 sites in the United States, patients ages 13–16 years were randomized in a double-blind manner to atomoxetine treatment by one of two dose titration schedules for 8 weeks. Patients who responded to treatment were rerandomized to atomoxetine at a daily dose of 0.8 or 1.4 mg/kg for 40 weeks. Patients in the highest-risk quartile for each category of behavior or domain were included and the dosing groups combined. Efficacy measures included the Youth Risk Behavior Surveillance (YRBS) and Child Health and Illness Profile – Adolescent Edition (CHIP-AE). The YRBS has six categories of behavior, and the CHIP-AE has six domains. Data for mean change from baseline were analyzed using a last-observation-carried-forward analysis. A total of 267 patients were randomized, but the high-risk subgroup analyzed in the present study was much smaller (range of n = 5–68 per group). YRBS scores for tobacco use, unhealthful dietary behaviors, inadequate physical activity, and behaviors contributing to unintentional injuries showed statistically significant improvements (p < 0.05) by atomoxetine treatment at Week 8. At the end of the 40-week maintenance period, unhealthful dietary behaviors, inadequate physical activity, and behaviors contributing to unintentional injuries continued to show statistically significant improvements (p < 0.001). When the highest-risk quartile of the CHIP-AE data was analyzed, there were statistically significant improvements on all six domains after atomoxetine treatment at 8 weeks (p < 0.001) and on five of the six domains at 40 weeks (p ≤ 0.01). Atomoxetine improved self-reported high-risk behaviors and overall health-related quality of life in adolescents with ADHD. Potential limitations of this study include small sample sizes and the fact that it involved a subgroup analysis, which is by nature hypothesis-generating. Further, well-controlled, prospective studies in larger and more heterogeneous ADHD populations, including older patients, are warranted to confirm or reject these findings.Keywords
This publication has 35 references indexed in Scilit:
- Atomoxetine Treatment in Adolescents with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2009
- Correlates of co-occurring ADHD in drug-dependent subjects: Prevalence and features of substance dependence and psychiatric disordersAddictive Behaviors, 2008
- Age of Methylphenidate Treatment Initiation in Children With ADHD and Later Substance Abuse: Prospective Follow-Up Into AdulthoodAmerican Journal of Psychiatry, 2008
- ADHD, Substance Use Disorders, and Psychostimulant TreatmentJournal of Attention Disorders, 2007
- A Critical Review of Self-perceptions and the Positive Illusory Bias in Children with ADHDClinical Child and Family Psychology Review, 2007
- A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)Current Medical Research and Opinion, 2007
- Behavioral Predictors of Substance-Use Initiation in Adolescents With and Without Attention-Deficit/Hyperactivity DisorderPediatrics, 2006
- Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderEuropean Child & Adolescent Psychiatry, 2006
- Psychostimulant Treatment and Risk for Substance Abuse Among Young Adults with a History of Attention-Deficit/Hyperactivity Disorder: APopulation-Based, Birth Cohort StudyJournal of Child and Adolescent Psychopharmacology, 2005
- Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorderJournal of Substance Abuse, 1995